Regulatory document
Acellular Dermal Matrix (ADM) Products Used in Implant-Based Breast Reconstruction Differ…
FDA Safety Communications · Information · USA · Mar 31, 2021
Key facts
| Title | Acellular Dermal Matrix (ADM) Products Used in Implant-Based Breast Reconstruction Differ in Complication Rates: FDA Safety Communication |
|---|---|
| Issuer | FDA Safety Communications |
| Source | FDA Safety Communications |
| Document type | Information |
| Country or region | USA |
| Date | Mar 31, 2021 |
| Document | fda.gov |
| Issuer website | fda.gov |
At a glance
- Yes Full text searchable in Orca1
- 100–999 Documents from this issuer in Orca1
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Global regulations and guidance
Regulations, guidance and official notices from medical device and medicines regulators worldwide, collected by Orca1 from each issuer's website. Only the title, issuer, date and link are shown here; the full text is searchable in Orca1.
Source: Medical device and medicines regulators and agencies as named on each record (EMA, MHRA, TGA, CDSCO, PMDA, NMPA, Health Canada, HSA, the FDA and others), collected by Orca1 from each issuer's website · Source date: